Stock Market Reviews

KMDA (Kamada Ltd.) News

Get the latest news, insights, and market updates on KMDA (Kamada Ltd.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Kamada (KMDA) is an Incredible Growth Stock: 3 Reasons Why
  Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
  Nov 11, 2025 - $KMDA
• Alpha-1 Antitrypsin Deficiency Disease Market Research Report 2025, Competitive Analysis of Shire, GSK, CSL Behring, AstraZeneca, Grifols, Teva Pharma, Boehringer Ingelheim, Kamada, Pfizer, Baxter
  The Alpha-1 Antitrypsin Deficiency Disease market offers opportunities in developing targeted therapies due to an increasing diagnosed patient population, advances in genetic testing, and innovative treatments like enzyme replacement and gene therapies. Growing awareness and technological advancements further drive this niche market. Alpha-1 Antitrypsin Deficiency Disease Market Alpha-1 Antitrypsin Deficiency Disease Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Defic
  Nov 11, 2025 - $KMDA
• Kamada Ltd (KMDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
  Kamada Ltd (KMDA) reports a 13% revenue increase and outlines future growth strategies amidst challenges in clinical trials and product sales.
  Nov 10, 2025 - $KMDA
• Kamada: Q3 Earnings Snapshot
  REHOVOT, Israel (AP) — Kamada Ltd. (KMDA) on Monday reported third-quarter earnings of $5.3 million. The Rehovot, Israel-based company said it had profit of 9 cents per share. The results missed Wall Street expectations.
  Nov 10, 2025 - $KMDA
• Kamada (KMDA) Misses Q3 Earnings Estimates
  Kamada (KMDA) delivered earnings and revenue surprises of -10.00% and +1.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 10, 2025 - $KMDA
• Kamada (KMDA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
  While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
  Nov 10, 2025 - $KMDA
• Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
  Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company's Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Generated $17.9 Million of Cash from Operations During First
  Nov 10, 2025 - $KMDA
• Regenxbio (RGNX) Reports Q3 Loss, Beats Revenue Estimates
  Regenxbio (RGNX) delivered earnings and revenue surprises of +13.04% and +23.73%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025 - $KMDA
• Countdown to Kamada (KMDA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
  Beyond analysts' top-and-bottom-line estimates for Kamada (KMDA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
  Nov 6, 2025 - $KMDA
• Ocugen (OCGN) Reports Q3 Loss, Beats Revenue Estimates
  Ocugen (OCGN) delivered earnings and revenue surprises of -16.67% and +46.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $KMDA